Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.51 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CCR4 | P51679 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030130 | 1.00 | NPBWR1 (0.53) | NPBWR1MCHR1CYP1A2SPHK1F2 | |
| SCHEMBL1815987 | 1.00 | NPBWR1 (0.53) | NPBWR1MCHR1CYP1A2SPHK1F2 | |
| SCHEMBL7814221 | 0.96 | NPBWR1 (0.58) | NPBWR1MCHR1SIGMAR1CD274PDCD1 | |
| SCHEMBL7814225 | 0.96 | NPBWR1 (0.58) | NPBWR1MCHR1SIGMAR1CD274PDCD1 | |
| Hydrochloric Acid SCHEMBL7618359 | 0.95 | NPBWR1 (0.57) | NPBWR1MCHR1F2CD274PDCD1 | |
| SCHEMBL7309417 | 0.88 | SPHK1 (0.63) | NPBWR1MCHR1SPHK1F2CD274 | |
| SCHEMBL6508602 | 0.87 | MAOB (0.65) | SPHK1CD274PDCD1 | |
| SCHEMBL6508605 | 0.87 | MAOB (0.65) | SPHK1CD274PDCD1 | |
| SCHEMBL1819248 | 0.87 | CYP1A2 (0.60) | MCHR1CYP1A2SPHK1CD274PDCD1 | |
| SCHEMBL1972076 | 0.87 | CYP1A2 (0.60) | MCHR1CYP1A2SPHK1CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | NPBWR1 941/4885MCHR1 2478/4885CYP1A2 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.